The mitochondrial anchor — and the register's cleanest "approved vs failed" split on one page. Three honest points define this entry: (1) as of September 2025 it is FDA-approved (Forzinity) for one ultra-rare disease — the first-ever approved therapy for a mitochondrial disease; (2) for the popular
SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin and stabilises the inner-membrane machinery that produces cellular energy. In September 2025 it became the first FDA-approved therapy for a mitochondrial disease — Barth syndrome — where a Phase 3 trial's open-label extension and a natural-history comparison showed improved muscle strength, walk distance and cardiac stroke volume over ~48 weeks. Crucially, its trials in the conditions people popularly associate it with have a much weaker record: the pivotal Barth randomized crossover phase and the primary mitochondrial myopathy Phase 3 both missed their primary endpoints, the heart-failure (HFpEF) program improved mitochondrial bioenergetics without functional benefit, and dry AMD results were mixed/negative. The "cellular energy / anti-aging" story rests almost entirely on aged-mouse studies, not human data.
investigational outside the US Barth indication.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (status evolving — accelerated approval requires a confirmatory trial; re-check the confirmatory-trial outcome and any label expansion).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.